Time-programmed activation of CD47 disruption and immunogenic cell death with Cas9 ribonucleoprotein nanocapsule for improved cancer immunotherapy

•Time-programmed activation strategy promotes the synergy of drug combinations.•The modular nanostructure achieves the targeted delivery of multiple drugs.•The combination of CD47 disruption and ICD can elicit robust antitumor immunity.•A universal platform enables the development of new cancer combination therapies.